Back to today’s briefing

Story perspectives

Abbott Q4 Sales Dip, But Diabetes Device Growth Soars

1/23/2025

28 5

Summary

Story summary

Abbott's Q4 sales reached $10.97 billion, falling short of the $11.03 billion estimate.
Medical device growth, especially in diabetes care, surged with a 22.7% revenue increase from FreeStyle Libre.
Adjusted EPS met expectations at $1.34.
For 2025, Abbott projects 7.5% to 8.5% sales growth and adjusted EPS of $5.05 to $5.25.
Analysts uphold a "Buy" rating, highlighting robust device sales amid foreign exchange challenges.

1 of 1

Story summary

Abbott's Q4 sales reached $10.97 billion, falling short of the $11.03 billion estimate.
Medical device growth, especially in diabetes care, surged with a 22.7% revenue increase from FreeStyle Libre.
Adjusted EPS met expectations at $1.34.
For 2025, Abbott projects 7.5% to 8.5% sales growth and adjusted EPS of $5.05 to $5.25.
Analysts uphold a "Buy" rating, highlighting robust device sales amid foreign exchange challenges.